SRR1797260
— · cohortSC
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSC
- subtype
- cohortSC
- age_years
- 52
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PANCREAS_BETA_CELLS+0.360
- COAGULATION+0.230
- KRAS_SIGNALING_DN+0.230
- SPERMATOGENESIS+0.230
- ALLOGRAFT_REJECTION+0.160
- APICAL_JUNCTION+0.150
- APICAL_SURFACE+0.120
- BILE_ACID_METABOLISM+0.060
- HEDGEHOG_SIGNALING+0.060
- XENOBIOTIC_METABOLISM+0.060
Top 10 suppressed
- MYC_TARGETS_V1-0.450
- UNFOLDED_PROTEIN_RESPONSE-0.410
- OXIDATIVE_PHOSPHORYLATION-0.400
- ANDROGEN_RESPONSE-0.390
- TGF_BETA_SIGNALING-0.380
- PI3K_AKT_MTOR_SIGNALING-0.350
- PROTEIN_SECRETION-0.350
- UV_RESPONSE_DN-0.320
- E2F_TARGETS-0.310
- MTORC1_SIGNALING-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-1143 | Med | Medulloblastoma | 0.943 |
| 2 | SRR12696762 | — | — | 0.933 |
| 3 | SRR1394566 | GTEX | — | 0.930 |
| 4 | SJEPD014_D.RNA-Seq | EPN | Posterior Fossa EPN | 0.927 |
| 5 | MNG436 | — | — | 0.925 |
| 6 | MNG339 | — | — | 0.925 |
| 7 | SRR1419714 | GTEX | — | 0.924 |
| 8 | MNG1137 | — | — | 0.923 |
| 9 | MDT-AP-0123 | Med | Medulloblastoma | 0.921 |
| 10 | MNG1159 | — | — | 0.921 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 12 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PANCREAS_BETA_CELLS | 0.360 | Cobimetinib | — uncovered |
| COAGULATION | 0.230 | Binimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.230 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.230 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.160 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.150 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.120 | Temsirolimus | — uncovered |
| BILE_ACID_METABOLISM | 0.060 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.060 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.060 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.020 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.010 | Idelalisib | — uncovered |